SCHEMBL2187184

SCHEMBL2187184

C=C(CN(C)C)C(=O)NC

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.42
PAX8 Q06710 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17777793 0.81 CA12 (0.37) EGFR
SCHEMBL2190725 0.77 EGFR (0.40) EGFRPAX8
SCHEMBL9319960 0.76 EGFR (0.39) EGFRPAX8
SCHEMBL19442312 0.76 EGFR (0.39) EGFRPAX8
SCHEMBL7868646 0.74 NPC1 (0.40) EGFRPAX8
SCHEMBL7166020 0.74 LMNA (0.35)
SCHEMBL5965047 0.73 EGFR (0.37) EGFRPAX8
SCHEMBL1082715 0.73 TSHR (0.39) EGFRPAX8
SCHEMBL25144748 0.72
SCHEMBL5673103 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017012963-A1 POLYMERIZABLE FATTY ACID-DERIVATIVE-MONOMERS WITH TERMINAL OLEFINIC DOUBLE BONDS, POLYMERS CONTAINING SAME MONOMERS, PRODUCTION AND USE THEREOF BASF SE (DE) 2017-01-26 WO claimed
EP-4355798-A1 BIODEGRADABLE GRAFT POLYMERS BASF SE (DE) 2024-04-24 EP disclosed
WO-2022263354-A1 BIODEGRADABLE GRAFT POLYMERS BASF SE (DE) 2022-12-22 WO disclosed
EP-2342079-B1 USE OF COMPOSITE FILMS AS A PACKAGING MATERIAL FOR OXIDATION-SENSITIVE POLYMERS, METHOD FOR PACKAGING OXIDATION-SENSITIVE POLYMERS, AND PACKAGING FORMS CONTAINING SAID COMPOSITE FILMS BASF SE (DE) 2018-06-20 EP disclosed
US-9982074-B2 Use of composite films as a packaging material for oxidation-sensitive polymers, method for packaging oxidation-sensitive polymers, and packaging containing said composite films BASF SE (DE) 2018-05-29 US disclosed
US-9783524-B2 Protein tyrosine kinase modulators and methods of use BETTA PHARMACEUTICALS CO., LTD. (CN) 2017-10-10 US disclosed
WO-2017012963-A1 POLYMERIZABLE FATTY ACID-DERIVATIVE-MONOMERS WITH TERMINAL OLEFINIC DOUBLE BONDS, POLYMERS CONTAINING SAME MONOMERS, PRODUCTION AND USE THEREOF BASF SE (DE) 2017-01-26 WO disclosed
US-20160145237-A1 PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE BETTA PHARMACEUTICALS CO., LTD (CN) 2016-05-26 US disclosed
US-20110257339-A1 METHOD FOR STABILIZING POLYMERS BASF SE (DE) 2011-10-20 US disclosed
US-20110220534-A1 USE OF COMPOSITE FILMS AS A PACKAGING MATERIAL FOR OXIDATION-SENSITIVE POLYMERS, METHOD FOR PACKAGING OXIDATION-SENSITIVE POLYMERS, AND PACKAGING CONTAINING SAID COMPOSITE FILMS BASF SE (DE) 2011-09-15 US disclosed
EP-2342079-A1 USE OF COMPOSITE FILMS AS A PACKAGING MATERIAL FOR OXIDATION-SENSITIVE POLYMERS, METHOD FOR PACKAGING OXIDATION-SENSITIVE POLYMERS, AND PACKAGING FORMS CONTAINING SAID COMPOSITE FILMS BASF SE (DE) 2011-07-13 EP disclosed
WO-2010072640-A9 METHOD FOR STABILIZING POLYMERS BASF SE (DE) 2010-12-23 WO disclosed
WO-2010072640-A1 METHOD FOR STABILIZING POLYMERS BASF SE (DE) 2010-07-01 WO disclosed
WO-2010052088-A1 USE OF COMPOSITE FILMS AS A PACKAGING MATERIAL FOR OXIDATION-SENSITIVE POLYMERS, METHOD FOR PACKAGING OXIDATION-SENSITIVE POLYMERS, AND PACKAGING FORMS CONTAINING SAID COMPOSITE FILMS BASF SE (DE) 2010-05-14 WO disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 US disclosed
US-20080200433-A1 Molecular Chaperone Function Regulator MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-21 US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145237-A1 PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE ALK, EGFR, ERBB2 EGFR 2/4885PAX8 4096/4885
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 EGFR 1535/4885PAX8 2006/4885
US-20080200433-A1 Molecular Chaperone Function Regulator HSPBP1, HSF1, HSPH1 EGFR 4772/4885PAX8 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.